184 related articles for article (PubMed ID: 18640130)
21. [Respiratory depression following medication change from tramadol to morphine].
Banning AM
Ugeskr Laeger; 1999 Nov; 161(47):6500-1. PubMed ID: 10778358
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
Arafa MH; Atteia HH
Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
[TBL] [Abstract][Full Text] [Related]
23. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype.
Stamer UM; Stüber F
Anaesthesia; 2007 Dec; 62(12):1294-5; author reply 1295-6. PubMed ID: 17991273
[No Abstract] [Full Text] [Related]
24. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
26. [Importance of the formulation for a chronopharmacologically optimised way of pain therapy. Results of a comparative bioavailability study of tramadol extended-release capsules after single-dose evening versus morning administration].
Warnke A; Schug B; Vanderbist F; Blume H
MMW Fortschr Med; 2008 Apr; 150 Suppl 1():36-42. PubMed ID: 18540331
[TBL] [Abstract][Full Text] [Related]
27. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
Abdel-Rahman SM; Leeder JS; Wilson JT; Gaedigk A; Gotschall RR; Medve R; Liao S; Spielberg SP; Kearns GL
J Clin Pharmacol; 2002 Jan; 42(1):24-9. PubMed ID: 11808821
[TBL] [Abstract][Full Text] [Related]
28. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
29. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.
Stamer UM; Stüber F; Muders T; Musshoff F
Anesth Analg; 2008 Sep; 107(3):926-9. PubMed ID: 18713907
[TBL] [Abstract][Full Text] [Related]
30. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
[TBL] [Abstract][Full Text] [Related]
31. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
32. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration.
Shilo Y; Britzi M; Eytan B; Lifschitz T; Soback S; Steinman A
J Vet Pharmacol Ther; 2008 Feb; 31(1):60-5. PubMed ID: 18177320
[TBL] [Abstract][Full Text] [Related]
34. Development of a linear dual column HPLC-MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid.
Yu H; Hong S; Jeong CH; Bae JW; Lee S
Arch Pharm Res; 2018 Mar; 41(3):288-298. PubMed ID: 29196917
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
Salman S; Sy SK; Ilett KF; Page-Sharp M; Paech MJ
Eur J Clin Pharmacol; 2011 Sep; 67(9):899-908. PubMed ID: 21394525
[TBL] [Abstract][Full Text] [Related]
36. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
[TBL] [Abstract][Full Text] [Related]
37. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood.
Levo A; Koski A; Ojanperä I; Vuori E; Sajantila A
Forensic Sci Int; 2003 Jul; 135(1):9-15. PubMed ID: 12893130
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response.
Slanar O; Nobilis M; Kvetina J; Idle JR; Perlík F
Eur J Clin Pharmacol; 2006 Jan; 62(1):75-6; author reply 77-8. PubMed ID: 16283276
[No Abstract] [Full Text] [Related]
39. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
40. A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.
Borlak J; Hermann R; Erb K; Thum T
Metabolism; 2003 Nov; 52(11):1439-43. PubMed ID: 14624403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
